Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
- SEC Filings
- Quarterly Results
Corporate Governance
Resources

News Releases

Year

Jun 13 / 23

Belite Bio Receives Approval to Initiate Tinlarebant (LBS-008) Phase 3 Clinical Trial for Stargardt Disease in South Korea

Jun 07 / 23

Belite Bio Announces EC Submission for Tinlarebant Phase 3 GA Clinical Trial in Australia

May 30 / 23

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

May 30 / 23

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

May 10 / 23

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

May 10 / 23

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

May 04 / 23

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

Apr 25 / 23

Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting

Apr 11 / 23

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 10 - 18 of 24

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio